Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals
- 333 Downloads
High pharmaceutical prices and over-prescribing of high-priced pharmaceuticals in Chinese hospitals has long been criticized. Although policy makers have tried to address these issues, they have not yet found an effective balance between government regulation and market forces.
Our objective was to explore the impact of market competition on pharmaceutical pricing under Chinese government regulation.
Data from 11 public tertiary hospitals in three cities in China from 2002 to 2005 were used to explore the effect of generic and therapeutic competition on prices of antibiotics and cardiovascular products. A quasi-hedonic regression model was employed to estimate the impact of competition. The inputs to our model were specific attributes of the products and manufacturers, with the exception of competition variables.
Our results suggest that pharmaceutical prices are inversely related to the number of generic and therapeutic competitors, but positively related to the number of therapeutic classes. In addition, the product prices of leading local manufacturers are not only significantly lower than those of global manufacturers, but are also lower than their non-leading counterparts when other product attributes are controlled for.
Under the highly price-regulated market in China, competition from generic and therapeutic competitors did decrease pharmaceutical prices. Further research is needed to explore whether this competition increases consumer welfare in China’s healthcare setting.
KeywordsAnatomical Therapeutic Chemical Bidding Price Generic Molecule Therapeutic Category Pharmaceutical Price
This study is funded by the National Natural Science Foundation of China (Grant Number 71203155) and Humane Social Science Fund Project of Ministry of Education China (Grant Number 13YJAZH108). All authors contributed to all aspects of the paper. J. Wu is the guarantor for the overall content of this paper. The authors have no conflicts of interest that are directly relevant to the contents of this study.
- 5.State Council of P.R. China. Opinions of the CPC Central Committee and the State Council on Deepening the Health Care System Reform (in Chinese). Beijing: State Council of P.R. China; 2009.Google Scholar
- 6.Ministry of Health of P.R. China. China Health Statistical Summary 2012; 2012. http://www.moh.gov.cn/mohwsbwstjxxzx/s7967/201206/55044.shtml (13 Sep 2013).
- 7.Wang LJ, Ge J. Background and evolution of hospital pharmaceuticals group procurement scheme (in Chinese). Chin J Health Policy. 2009;12:8–13.Google Scholar
- 9.Wang W. A new round of reducing drugs prices for insurance reimbursement list: the new listed drugs may be reduced by 5%. China Business News Mar 1; Sect B01; 2012.Google Scholar
- 10.Chinese Medical Database Net. Chinese Medical Statistical Yearbook (in Chinese). Beijing: Chinese Medical Database Net; 2005.Google Scholar
- 12.Briefing reports on the national drug safety special rectification work. Government document  37. State Food and Drug Administration; 2012. http://www.sfda.gov.cn/WS01/CL0844/69246_7.html (30 Mar 2013).
- 13.National Development and Reform Commission (NDRC). The method of government drug pricing; the advice on further regulating medicine prices and health care services price (in Chinese). Beijing: NDRC; 2006.Google Scholar
- 14.Yang SJ, Chen J, Wang SL. Promote the development of imitation pharmaceuticals in China (in Chinese). World Clin Drugs. 2009;30:121–4.Google Scholar
- 16.State Council of P.R. China. White paper: status quo of drug supervision in China. http://www.gov.cn/english/2008-07/18/content_1049011.htm (30 Sep 2010).
- 17.Liang Y. Drug representatives disclose the rebates related to the high drug prices (in Chinese). Xi’an Med Inform. 2005;10:4–6.Google Scholar
- 19.Zhang M, Bian Y. History and effect of Chinese hospital pharmaceutical mark-up policy (in Chinese). J Chin Med Care Admin. 2007;229:465–6.Google Scholar
- 21.International Research Center of Medicinal Administration (IRCMA) Peking University. Information of Medicinal Administration (in Chinese). Beijing: International Research Center of Medicinal Administration Peking University; 2010.Google Scholar
- 22.Beijing Ministry of Health. Pharmaceuticals group procurement scheme 2009 in Medical Institutions in Beijing (in Chinese). China Pharmacy. 2010;21:1088–91.Google Scholar
- 23.Liu WT. Essential medicine system distortions in local provinces: pharmaceutical prices are higher after bidding (in Chinese). People’s Daily Dec 29; Sect. F18; 2010.Google Scholar
- 24.Hu XL. Higher price after bidding process: ¥ 30 difference for a bottler of medicines (in Chinese). Market News Jun 07; Sect. F4; 2006.Google Scholar
- 33.South Pharmaceutical Economic Institute (SPEI) of State Food and Drug Administration. The competition of the top 100 pharmaceutical industries is challenging (in Chinese). Medical Economic News Aug 10; Sect. D 2; 2007.Google Scholar
- 35.Rosen S. Hedonic prices and implicit markets: product differentiation in pure competition. J Polit Econ. 1974;82:35–55.Google Scholar
- 36.Geng HW. Asparagus tablets are the best annotation of the “medical lemon market” (in Chinese). Medical Economic News Jun 21; Sect. F 2; 2010.Google Scholar